Cargando…
Lipidomics in non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disorder in Western countries, comprises steatosis to nonalcoholic steatohepatitis (NASH), with the latter having the potential to progress to cirrhosis. The transition from isolated steatosis to NASH is still poorly understood...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475773/ https://www.ncbi.nlm.nih.gov/pubmed/32952872 http://dx.doi.org/10.4254/wjh.v12.i8.436 |
_version_ | 1783579581362470912 |
---|---|
author | Kartsoli, Sofia Kostara, Christina E Tsimihodimos, Vasilis Bairaktari, Eleni T Christodoulou, Dimitrios K |
author_facet | Kartsoli, Sofia Kostara, Christina E Tsimihodimos, Vasilis Bairaktari, Eleni T Christodoulou, Dimitrios K |
author_sort | Kartsoli, Sofia |
collection | PubMed |
description | Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disorder in Western countries, comprises steatosis to nonalcoholic steatohepatitis (NASH), with the latter having the potential to progress to cirrhosis. The transition from isolated steatosis to NASH is still poorly understood, but lipidomics approach revealed that the hepatic lipidome is extensively altered in the setting of steatosis and steatohepatitis and these alterations correlate with disease progression. Recent data suggest that both quantity and quality of the accumulated lipids are involved in pathogenesis of NAFLD. Changes in glycerophospholipid, sphingolipid, and fatty acid composition have been described in both liver biopsies and plasma of patients with NAFLD, implicating that specific lipid species are involved in oxidative stress, inflammation, and cell death. In this article, we summarize the findings of main human lipidomics studies in NAFLD and delineate the currently available information on the pathogenetic role of each lipid class in lipotoxicity and disease progression. |
format | Online Article Text |
id | pubmed-7475773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-74757732020-09-18 Lipidomics in non-alcoholic fatty liver disease Kartsoli, Sofia Kostara, Christina E Tsimihodimos, Vasilis Bairaktari, Eleni T Christodoulou, Dimitrios K World J Hepatol Review Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disorder in Western countries, comprises steatosis to nonalcoholic steatohepatitis (NASH), with the latter having the potential to progress to cirrhosis. The transition from isolated steatosis to NASH is still poorly understood, but lipidomics approach revealed that the hepatic lipidome is extensively altered in the setting of steatosis and steatohepatitis and these alterations correlate with disease progression. Recent data suggest that both quantity and quality of the accumulated lipids are involved in pathogenesis of NAFLD. Changes in glycerophospholipid, sphingolipid, and fatty acid composition have been described in both liver biopsies and plasma of patients with NAFLD, implicating that specific lipid species are involved in oxidative stress, inflammation, and cell death. In this article, we summarize the findings of main human lipidomics studies in NAFLD and delineate the currently available information on the pathogenetic role of each lipid class in lipotoxicity and disease progression. Baishideng Publishing Group Inc 2020-08-27 2020-08-27 /pmc/articles/PMC7475773/ /pubmed/32952872 http://dx.doi.org/10.4254/wjh.v12.i8.436 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Review Kartsoli, Sofia Kostara, Christina E Tsimihodimos, Vasilis Bairaktari, Eleni T Christodoulou, Dimitrios K Lipidomics in non-alcoholic fatty liver disease |
title | Lipidomics in non-alcoholic fatty liver disease |
title_full | Lipidomics in non-alcoholic fatty liver disease |
title_fullStr | Lipidomics in non-alcoholic fatty liver disease |
title_full_unstemmed | Lipidomics in non-alcoholic fatty liver disease |
title_short | Lipidomics in non-alcoholic fatty liver disease |
title_sort | lipidomics in non-alcoholic fatty liver disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475773/ https://www.ncbi.nlm.nih.gov/pubmed/32952872 http://dx.doi.org/10.4254/wjh.v12.i8.436 |
work_keys_str_mv | AT kartsolisofia lipidomicsinnonalcoholicfattyliverdisease AT kostarachristinae lipidomicsinnonalcoholicfattyliverdisease AT tsimihodimosvasilis lipidomicsinnonalcoholicfattyliverdisease AT bairaktarielenit lipidomicsinnonalcoholicfattyliverdisease AT christodouloudimitriosk lipidomicsinnonalcoholicfattyliverdisease |